Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

JAK2V617F mutation and circulating extracellular vesicles in essential thrombocythemia

MH. Aswad, J. Kissova, P. Ovesna, L. Říhová, M. Penka

. 2023 ; 84 (4) : 359-368. [pub] -

Jazyk angličtina Země Nizozemsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc23017107

The clinical course of essential thrombocythemia (ET) is complicated with thrombosis which significantly impacts patients' mortality. Studies have identified JAK2V617F mutation as an independent risk factor for thrombosis. Circulating extracellular vesicles (EVs) were evaluated in several studies regarding myeloproliferative neoplasms and thrombosis as potential biomarkers. The present study investigates the relationship between JAK2V617F mutation and EVs levels in 119 ET patients. Our analyses revealed that JAK2V617F-positive patients are at a significantly increased risk of thrombosis within five years before the ET diagnosis (hazard ratio [95% CI]: 11.9 [1.7-83.7], P = 0.013), and that JAK2V617F mutation is an independent risk factor for thrombosis at ET diagnosis or during the follow-up (hazard ratio [95% CI]: 3.56 [1.47-8.62], P = 0.005). ET patients have higher levels of platelet-EVs, erythrocyte-EVs and procoagulant activity of EVs than the healthy population. Absolute and relative counts of platelet-EVs are increased in the presence of JAK2V617F mutation (P = 0.018, P = 0.024, respectively). In conclusion, our results support the role of JAK2V617F mutation in the pathogenesis of thrombosis in essential thrombocythemia through enhancing platelet activation.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23017107
003      
CZ-PrNML
005      
20231026105414.0
007      
ta
008      
231013s2023 ne f 000 0|eng||
009      
AR
024    7_
$a 10.3233/CH-221678 $2 doi
035    __
$a (PubMed)37334581
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Aswad, Mohamed Hussam $u Department of Clinical Hematology, Faculty of Medicine, University Hospital Brno, Brno, Czech Republic $u Faculty of Medicine, Masaryk University, Brno, Czech Republic
245    10
$a JAK2V617F mutation and circulating extracellular vesicles in essential thrombocythemia / $c MH. Aswad, J. Kissova, P. Ovesna, L. Říhová, M. Penka
520    9_
$a The clinical course of essential thrombocythemia (ET) is complicated with thrombosis which significantly impacts patients' mortality. Studies have identified JAK2V617F mutation as an independent risk factor for thrombosis. Circulating extracellular vesicles (EVs) were evaluated in several studies regarding myeloproliferative neoplasms and thrombosis as potential biomarkers. The present study investigates the relationship between JAK2V617F mutation and EVs levels in 119 ET patients. Our analyses revealed that JAK2V617F-positive patients are at a significantly increased risk of thrombosis within five years before the ET diagnosis (hazard ratio [95% CI]: 11.9 [1.7-83.7], P = 0.013), and that JAK2V617F mutation is an independent risk factor for thrombosis at ET diagnosis or during the follow-up (hazard ratio [95% CI]: 3.56 [1.47-8.62], P = 0.005). ET patients have higher levels of platelet-EVs, erythrocyte-EVs and procoagulant activity of EVs than the healthy population. Absolute and relative counts of platelet-EVs are increased in the presence of JAK2V617F mutation (P = 0.018, P = 0.024, respectively). In conclusion, our results support the role of JAK2V617F mutation in the pathogenesis of thrombosis in essential thrombocythemia through enhancing platelet activation.
650    _2
$a lidé $7 D006801
650    12
$a esenciální trombocytemie $x genetika $x komplikace $x patologie $7 D013920
650    12
$a trombóza $x genetika $x patologie $7 D013927
650    12
$a myeloproliferativní poruchy $x komplikace $x genetika $x patologie $7 D009196
650    _2
$a mutace $7 D009154
650    _2
$a trombocyty $7 D001792
650    _2
$a Janus kinasa 2 $x genetika $7 D053614
655    _2
$a časopisecké články $7 D016428
700    1_
$a Kissova, Jarmila $u Department of Clinical Hematology, Faculty of Medicine, University Hospital Brno, Brno, Czech Republic $u Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Ovesna, Petra $u Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Říhová, Lucie $u Department of Clinical Hematology, Faculty of Medicine, University Hospital Brno, Brno, Czech Republic $u Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Penka, Miroslav $u Department of Clinical Hematology, Faculty of Medicine, University Hospital Brno, Brno, Czech Republic $u Faculty of Medicine, Masaryk University, Brno, Czech Republic
773    0_
$w MED00007160 $t Clinical hemorheology and microcirculation $x 1875-8622 $g Roč. 84, č. 4 (2023), s. 359-368
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37334581 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20231013 $b ABA008
991    __
$a 20231026105408 $b ABA008
999    __
$a ok $b bmc $g 2000565 $s 1203469
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 84 $c 4 $d 359-368 $e - $i 1875-8622 $m Clinical hemorheology and microcirculation $n Clin Hemorheol Microcirc $x MED00007160
LZP    __
$a Pubmed-20231013

Najít záznam

Citační ukazatele

Možnosti archivace